A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Embecta Corp. (also referred to herein as "Embecta") is a leading global medical device company, primarily focused on providing solutions to improve the health and well-being of people living with diabetes. All references in this Form 10-K to "Embecta", "the Company", "we", "our" or "us" refer to Embecta Corp., a Delaware corporation, and its subsidiaries, unless otherwise indicated by the context. Building on our 100-year centennial, we believe that our products have become one of the most widely recognized and respected brands in diabetes management throughout the world. We estimate that our products are used by more than 30 million people in over 100 countries for insulin administration and to aid with the daily management of diabetes. We have a broad portfolio of marketed products, including a variety of pen needles, syringes and safety injection devices.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 1.1B | 1.1B | 1.1B | 1.1B | 1.1B | 1.2B |
| Net Income | 140M | 95M | 78M | 70M | 224M | 415M |
| EPS | $2.38 | $1.62 | $1.34 | $1.22 | $3.89 | $7.28 |
| Free Cash Flow | 206M | 182M | 20M | 41M | 389M | 420M |
| ROIC | 38.6% | 31.3% | 32.9% | 35.5% | 55.1% | 70.5% |
| Gross Margin | 63.1% | 62.6% | 65.5% | 66.9% | 68.6% | 68.7% |
| Debt/Equity | 0.00 | -2.15 | -2.13 | -1.95 | -1.80 | 0.01 |
| Dividends/Share | $0.59 | $0.60 | $0.60 | $0.60 | $0.15 | $0.00 |
| Operating Income | 297M | 242M | 167M | 222M | 310M | 492M |
| Operating Margin | 27.5% | 22.4% | 14.9% | 19.8% | 27.4% | 42.2% |
| ROE | 0.0% | -13.7% | -10.0% | -8.2% | -150.5% | 71.1% |
| Shares Outstanding | 59M | 59M | 58M | 58M | 57M | 57M |
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 1.1B | 1.2B | 1.1B | 1.1B | 1.1B | 1.1B | 1.1B |
| Gross Margin | 70.3% | 68.7% | 68.6% | 66.9% | 65.5% | 62.6% | 63.1% |
| R&D | 61M | 63M | 67M | 85M | 79M | 37M | 22M |
| SG&A | 215M | 240M | 295M | 341M | 365M | 332M | 329M |
| EBIT | 487M | 492M | 310M | 222M | 167M | 242M | 297M |
| Op. Margin | 44.8% | 42.2% | 27.4% | 19.8% | 14.9% | 22.4% | 27.5% |
| Net Income | 428M | 415M | 224M | 70M | 78M | 95M | 140M |
| Net Margin | 39.4% | 35.6% | 19.8% | 6.3% | 7.0% | 8.8% | 12.9% |
| Non-Recurring | 0 | 0 | 0 | 8.1M | 7.4M | 38M | 11M |
| Returns on Capital | |||||||
| ROIC | 74.5% | 70.5% | 55.1% | 35.5% | 32.9% | 31.3% | 38.6% |
| ROE | 74.4% | 71.1% | -150.5% | -8.2% | -10.0% | -13.7% | 0.0% |
| ROA | N/A | 107.4% | 23.9% | 6.1% | 6.3% | 8.0% | 13.1% |
| Cash Flow | |||||||
| Op. Cash Flow | 499M | 456M | 412M | 68M | 36M | 192M | 214M |
| Free Cash Flow | 457M | 420M | 389M | 41M | 20M | 182M | 206M |
| Owner Earnings | 448M | 405M | 362M | 14M | -27M | 119M | 144M |
| CapEx | 42M | 37M | 24M | 27M | 16M | 9.3M | 8.4M |
| Maint. CapEx | 38M | 38M | 32M | 33M | 36M | 41M | 42M |
| Growth CapEx | 3.6M | 0 | 0 | 0 | 0 | 0 | 0 |
| D&A | 38M | 38M | 32M | 33M | 36M | 41M | 42M |
| CapEx/OCF | N/A | N/A | 5.7% | 39.1% | 44.3% | 4.9% | 3.9% |
| Capital Allocation | |||||||
| Dividends Paid | 0 | 0 | 8.6M | 34M | 35M | 35M | 35M |
| Dividend Yield | N/A | N/A | 0.6% | 2.6% | 4.4% | 4.5% | 6.3% |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 13M | 13M | 19M | 22M | 26M | 32M | 29M |
| Debt Repayment | 0 | 0 | 4.8M | 9.5M | 35M | 185M | 185M |
| Balance Sheet | |||||||
| Net Debt | 0 | 4.1M | 1.3B | 1.3B | 1.3B | 1.2B | 1.2B |
| Cash & Equiv. | 0 | 0 | 331M | 327M | 268M | 226M | 201M |
| Long-Term Debt | 0 | 0 | 1.6B | 1.6B | 1.6B | 1.4B | 1.4B |
| Debt/Equity | 0.00 | 0.01 | -1.80 | -1.95 | -2.13 | -2.15 | 0.00 |
| Interest Coverage | 167.8 | 123.0 | 206.4 | 1107.5 | 1668.0 | 220.1 | 220.1 |
| Equity | 572M | 594M | -891M | -822M | -738M | -651M | -613M |
| Total Assets | -15M | 788M | 1.1B | 1.2B | 1.3B | 1.1B | 1.1B |
| Total Liabilities | -3.8M | 194M | 2.0B | 2.0B | 2.0B | 1.7B | -24M |
| Intangibles | N/A | 18M | 8.9M | 9.1M | 8.1M | 7.0M | 6.7M |
| Retained Earnings | N/A | N/A | -577M | -541M | -499M | -446M | -411M |
| Working Capital | N/A | 128M | 364M | 396M | 387M | 370M | 385M |
| Current Assets | 0 | 292M | 665M | 749M | 761M | 631M | 620M |
| Current Liabilities | N/A | 164M | 301M | 354M | 374M | 262M | 235M |
| Per Share Data | |||||||
| EPS | 7.50 | 7.28 | 3.89 | 1.22 | 1.34 | 1.62 | 2.38 |
| Owner EPS | 7.85 | 7.11 | 6.29 | 0.24 | -0.46 | 2.03 | 2.43 |
| Book Value | 10.04 | 10.43 | -15.51 | -14.24 | -12.64 | -11.05 | -10.35 |
| Cash Flow/Share | 8.74 | 8.01 | 7.17 | 1.17 | 0.61 | 3.26 | 3.06 |
| Dividends/Share | 0.00 | 0.00 | 0.15 | 0.60 | 0.60 | 0.60 | 0.59 |
| Shares Out. | 57.0M | 57.0M | 57.5M | 57.7M | 58.4M | 58.9M | 59.2M |
| Valuation | |||||||
| P/E Ratio | N/A | N/A | 6.6 | 11.0 | 9.9 | 8.3 | 4.0 |
| P/FCF | N/A | N/A | 3.8 | 18.8 | 38.8 | 4.4 | 2.7 |
| EV/EBIT | N/A | N/A | 8.9 | 7.8 | 10.9 | 7.2 | 5.8 |
| Price/Book | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Sales | N/A | N/A | 1.3 | 1.2 | 0.7 | 0.7 | 0.5 |
| FCF Yield | N/A | N/A | 26.1% | 5.3% | 2.6% | 22.9% | 36.7% |
| Market Cap | N/A | N/A | 1.5B | 775M | 771M | 796M | 560M |
| Avg. Price | N/A | N/A | 26.05 | 23.11 | 13.33 | 13.34 | 9.46 |
| Year-End Price | N/A | N/A | 25.86 | 13.43 | 13.20 | 13.53 | 9.46 |
Embecta Corp. passes 4 of 9 quality checks, suggesting mixed fundamentals.
Embecta Corp. trades at 4.0x trailing earnings, compared to its 15-year median P/E of 9.1x, suggesting it is currently Cheap relative to its historical range. On a free-cash-flow basis, the stock trades at 2.7x vs a median of 11.6x. The company's 5-year average ROIC is 45.1% with a gross margin of 66.5%. Total shareholder yield (dividends) is 6.3%. At current prices, the estimated annualized return to fair value is -46.0%.
Embecta Corp. (EMBC) has a current P/E ratio of 4.0, compared to its historical median P/E of 9.1. The stock is currently considered Cheap based on its historical valuation range.
Embecta Corp. (EMBC) has a 5-year average return on invested capital (ROIC) of 45.1%. This indicates strong capital allocation and a potential competitive advantage.
Embecta Corp. (EMBC) has a market capitalization of $560M. It is classified as a small-cap stock.
Yes, Embecta Corp. (EMBC) pays a dividend with a trailing twelve-month yield of 6.27%.
Based on historical P/E analysis, Embecta Corp. (EMBC) appears cheap. The current P/E of 4.0 is 56% below its historical median of 9.1. The estimated fair value CAGR (P/E method) is -95.7%.
Embecta Corp. (EMBC) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
Embecta Corp. (EMBC) reported annual revenue of $1.1 billion in its most recent fiscal year, based on SEC EDGAR filings.
Embecta Corp. (EMBC) has a net profit margin of 8.8%. This is a modest margin.
Embecta Corp. (EMBC) generated $182 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Embecta Corp. (EMBC) reported earnings per share (EPS) of $1.62 in its most recent fiscal year.
Embecta Corp. (EMBC) has a return on equity (ROE) of -13.7%. A negative ROE may indicate losses or negative equity.
Embecta Corp. (EMBC) has a 5-year average gross margin of 66.5%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 6 years of financial data for Embecta Corp. (EMBC), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Embecta Corp. (EMBC) has a book value per share of $-11.05, based on its most recent annual SEC filing.